These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 15848674

  • 1. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
    Kato T, Yoshida H, Sadfar K, Martinez E, Nishida S, Moon J, Madariaga J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.
    Transplant Proc; 2005 Mar; 37(2):1217-9. PubMed ID: 15848674
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.
    Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A.
    Transplantation; 2007 Oct 15; 84(7):829-35. PubMed ID: 17984834
    [Abstract] [Full Text] [Related]

  • 3. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
    Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG.
    Liver Transpl; 2011 Dec 15; 17(12):1394-403. PubMed ID: 21850690
    [Abstract] [Full Text] [Related]

  • 4. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J, MARSILEA Study Group.
    Transplantation; 2008 Dec 27; 86(12):1689-94. PubMed ID: 19104406
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S, Lipscomb J, Eason J.
    Transplantation; 2008 Aug 15; 86(3):418-22. PubMed ID: 18698245
    [Abstract] [Full Text] [Related]

  • 7. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
    Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J.
    Clin Transplant; 2007 Aug 15; 21(4):526-31. PubMed ID: 17645714
    [Abstract] [Full Text] [Related]

  • 8. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.
    Transplant Proc; 2005 Mar 15; 37(2):1151-2. PubMed ID: 15848653
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation.
    Pelletier SJ, Vanderwall K, Debroy MA, Englesbe MJ, Sung RS, Magee JC, Fontana RJ, Punch JD.
    Transplant Proc; 2005 Mar 15; 37(2):1214-6. PubMed ID: 15848673
    [Abstract] [Full Text] [Related]

  • 13. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 14. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ.
    Liver Transpl; 2002 Jan 15; 8(1):40-6. PubMed ID: 11799484
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
    Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO.
    Transpl Int; 2001 Dec 15; 14(6):396-404. PubMed ID: 11793037
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
    Eurich D, Neumann UP, Boas-Knoop S, Neuhaus R, Kiessling A, Yahyazadeh A, Trautwein C, Wasmuth H, Puhl G, Neuhaus P, Bahra M.
    J Gastroenterol Hepatol; 2013 Jan 15; 28(1):153-60. PubMed ID: 22989351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.